Sanofi will invest €400 million over five years to create a new vaccine production site in Singapore leveraging cutting edge manufacturing and digital technologies. The new site will allow Sanofi to produce innovative vaccines on a massive scale for Asia, and quickly respond to future pandemic risks.
 
The Singapore site complements Sanofi’s existing manufacturing capacities in Europe and North America and will become a regional center of excellence for vaccines production in Asia.
 
The project is expected to create up to 200 local jobs and enhance Singapore’s position as a regional innovation hub for the healthcare industry.
 
“As a major healthcare player, it’s our responsibility to act and to meet the unprecedented growing demands for vaccines. By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands on vaccines, and answer more rapidly to future pandemics,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. “We are very pleased by the strong collaboration with the Singapore Economic Development Board to achieve this exciting milestone.”
 
The factory will be designed around a central unit housing several fully digitalized modules that allow production of three to four vaccines simultaneously, versus only one in current industrial sites. The factory will have the flexibility to leverage multiple vaccine manufacturing technology platforms based on different cell types, allowing the production of a specific vaccine to be prioritized in a faster timeframe depending on public health needs.
 
Construction is expected to begin in 3Q21 and will be fully operational in 1Q26 once all qualifications and validations of the first manufactured vaccine have been completed.